Podcasts about Prostate cancer

Diets rich in fruits and vegetables preserve brain function—but in vulnerable persons with the ApoE4 “Alzheimer's gene”, more meat staves off decline, contradicting years of recommendations to minimize animal protein; Supplements for adrenal insufficiency; “Forever chemicals” may weaken teen's bones—but menopausal hormone replacement therapy decisively fends off osteoporosis; Legionnaire's disease strikes poor and affluent alike in New York City; Doctors propose warning labels for GLP-1 drugs on account of this under-appreciated danger.

Mr. Jones from the We Got A Thing podcast called in to talk all about having prostate cancer, losing his erections and then swinging again years later. Tune in to hear how he found out he had prostate cancer despite having zero symptoms, why routine bloodwork and PSA testing probably saved his life, what his MRI, biopsy and Gleason score revealed, why he decided on surgery vs. radiation, what recovery was really like, how long he had to wear a catheter, when he regained bladder control, how and why he lost penis length after surgery, why he could no longer ejaculate, how prostate removal affected his erections and orgasms, why Viagra and Cialis didn't work for him, how Bimix helped him get his sex life back, what it was like returning to the swinging lifestyle after prostate cancer, why communication with his female partners became more important than ever, what every guy should know about PSA testing and prostate cancer screening, plus a whole lot more. To get in touch with him and join his mens only community you can email him at  mr.jones@wegottathing.com ir find them here: https://wegottathing.com GET A COPY OF THE STRICTLY ANONYMOUS BOOK! Strictly Anonymous Confessions: Secret Sex Lives of Total Strangers. A bunch of short, super sexy, TRUE stories. GET YOUR COPY HERE: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://amzn.to/4i7hBCd⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  or Pre-order audiobook version ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠   To see HOT pics of my female guests + hear anonymous confessions + get all the episodes early and AD FREE, join my Patreon! It's only $7 a month and you can cancel at any time. You can sign up here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/StrictlyAnonymousPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and when you join, I'll throw in a complimentary link to my private Discord! To join SDC and get a FREE Trial! click here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.sdc.com/?ref=37712⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or go to SDC.com and use my code 37712 Want to be on the show? Email me at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠strictlyanonymouspodcast@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.strictlyanonymouspodcast.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and click on "Be on the Show." Want to confess while remaining anonymous? Call the CONFESSIONS hotline at 347-420-3579. All voices are changed.   Sponsors:  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://beduc.at/pd2626-anonymous⁠⁠⁠⁠ Click here to take the quiz and  get your personalized SUMMER roadmap to sexual happiness ⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://Rythm.Health/STRICTLYANON⁠⁠⁠⁠⁠⁠ ⁠⁠for 15% OFF your first month  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://VB.Health⁠⁠⁠⁠⁠⁠⁠ - To get 10% off DRIVE BOOST by VB Health, use code: STRICTLY   ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bluechew.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ — Buy 2 months of Bluechew GOLD and get the third month FREE! Use code: STRICTLYANON⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Follow me! Instagram  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/strictanonymous/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ X  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/strictanonymous?lang=en⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Website  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.strictlyanonymouspodcast.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Everything else: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/Strictlyanonymouspodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us Fan MailLifestyle and patient choices in Prostate CancerProstate cancer has been part of a revolution in terms of treatment options and improved outcomes for our patients. How can we make that improvement in numbers on survival curves match the goals and needs of our patients?Join us in this first of 2 special live episodes of the Simply Oncology Podcast on Patient Choices and Lifestyle in Prostate Cancer.We talk to patient expert Tony Collier, Dr Lucy Gossage - an oncologist involved with Move Against Cancer and  Professor Alison Birtle an oncologist with extensive experience treating prostate cancer.In this Episode  we talk to Tony Collier about his experience of being a prostate cancer patient. We hear how the focus on treatment led him to have to advocate his quality of life and life goals himself. We hear how clinicians could align with patients' goals with just a few simple questions. We hear about the huge positive impact that maintaining exercise has had on Tony's life with cancer. Hearing Tony's live experience of some very personal aspects of a cancer diagnosis and treatment is hugely moving and powerful.We hope you enjoy!*This is a non-promotional podcast episode organised by Bayer PLC in partnership with Simply Oncology (Dr John McGrane and Dr Michael Rowe) to highlight the importance of holistic care in managing patients with prostate cancer. Bayer provided honoraria to the speakers of this podcast. The views and opinions expressed are those of the speakers and do not necessarily reflect those of Bayer PLC or Simply Oncology. This content is for educational purposes only and should not replace clinical judgement.*

Can focal therapy truly “thread the needle” between active surveillance and radical prostate cancer treatment? In this episode of BackTable Urology, host Dr. Tiwa Akinsola is joined by Dr. George Schade from the University of Washington to explore focal therapy as a middle ground between active surveillance and radical treatments. Dr. Schade reviews non-radiation energy modalities including HIFU, TULSA/HI-DU, cryotherapy, and irreversible electroporation, highlighting patient selection, institutional experience, technical nuances, and quality-of-life outcomes from recent trials. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps00:00 - Introduction02:09 - Overview of Focal Therapy Modalities04:46 - Deciding Between HIFU and IRE06:56 - Evidence and Trials09:40 - Counseling Patients on Outcomes12:09 - Building a Focal Therapy Program16:12 - Navigating Insurance and Appeals21:48 - Managing Large Glands And TURP25:12 - Preop Workup Essentials and OR Workflow32:32 - Overcoming the Learning Curve35:52 - PostOp Recovery and Surveillance39:04 - Options for Managing Recurrence42:44 - Challenges with Repeat Ablation44:56 - Final Takeaways --- More about this episodeThe conversation covers candidate selection and confirmatory biopsy, perioperative technique and recovery, and ongoing surveillance with PSA, MRI, and biopsy. Dr. Schade also discusses challenges with insurance approvals, building a focal therapy practice, and options for managing recurrence, including repeat ablation, surgery, or radiation. The episode examines how to balance cancer control with quality of life and reviews the evolving evidence base supporting focal therapy's role in prostate cancer treatment. --- Resources Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial:https://www.sciencedirect.com/science/article/pii/S030228382500346X Focal therapy of localized prostate cancerhttps://pubmed.ncbi.nlm.nih.gov/35996758/ Focal Therapy for Prostate Cancer: Available Technologies, Patient Selection, Follow-Up Protocols and Reported Outcomeshttps://pubmed.ncbi.nlm.nih.gov/41339218/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.► https://www.backtable.com/app

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QSP865. CME/MOC/AAPA credit will be available until June 29, 2027.Continuing the Innovation Story in Prostate Cancer: Novel Advances and Therapeutic Expansions Across Disease Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Prostate Net. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FMP865. CME/MOC/AAPA/IPCE credit will be available until June 16, 2027.Next-Generation Treatment Pathways in Prostate Cancer: Practical Case-Driven Guidance to Individualize Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Blue Earth Diagnostics.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FMP865. CME/MOC/AAPA/IPCE credit will be available until June 16, 2027.Next-Generation Treatment Pathways in Prostate Cancer: Practical Case-Driven Guidance to Individualize Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Blue Earth Diagnostics.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QSP865. CME/MOC/AAPA credit will be available until June 29, 2027.Continuing the Innovation Story in Prostate Cancer: Novel Advances and Therapeutic Expansions Across Disease Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Prostate Net. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FMP865. CME/MOC/AAPA/IPCE credit will be available until June 16, 2027.Next-Generation Treatment Pathways in Prostate Cancer: Practical Case-Driven Guidance to Individualize Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Blue Earth Diagnostics.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QSP865. CME/MOC/AAPA credit will be available until June 29, 2027.Continuing the Innovation Story in Prostate Cancer: Novel Advances and Therapeutic Expansions Across Disease Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Prostate Net. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FMP865. CME/MOC/AAPA/IPCE credit will be available until June 16, 2027.Next-Generation Treatment Pathways in Prostate Cancer: Practical Case-Driven Guidance to Individualize Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Blue Earth Diagnostics.Disclosure information is available at the beginning of the video presentation.

Dr. Fred Saad, Uro-oncologist at the CHUM and prostate cancer researcher at the Montreal Cancer Institute. He is one of the researchers in this study

In this episode of All Talk Oncology, host Kenny Perkins (Your Cancer Guy) sits down with legendary R&B artist Montell Jordan for an honest and deeply personal conversation about his battle with prostate cancer. Known worldwide for the iconic hit “This Is How We Do It,” Montell opens up about life beyond music and shares what it was like receiving a cancer diagnosis after a routine annual physical. Initially diagnosed with early-stage prostate cancer, Montell discusses the difficult decisions surrounding treatment, the emotional toll of recurrence, and how his unwavering faith helped him navigate one of the hardest battles of his life. Montell candidly speaks about the realities many men don't openly discuss—fear, masculinity, intimacy after treatment, mental resilience, and the impact cancer has on relationships and family dynamics. He also highlights the vital role caregivers play and how his wife helped sustain him through treatment and recovery. Most importantly, Montell emphasizes the life-saving importance of early detection and PSA screening, especially for African American men who are at higher risk for prostate cancer. This powerful episode is filled with encouragement, practical insight, and hope for patients, caregivers, survivors, and families navigating cancer. In this episode, Montell Jordan discusses the following: His life and career before cancer Receiving a prostate cancer diagnosis after a routine physical Why annual screenings and PSA testing matter Understanding Gleason scores and prostate cancer staging The treatment decision process: watch, treat, radiate, or remove Undergoing a radical prostatectomy Facing cancer recurrence and navigating proton therapy How faith shaped his mindset during treatment The emotional impact of cancer on spouses and caregivers Why empathy, not sympathy is critical during cancer care Intimacy and relationships after prostate cancer treatment Advocacy for men's health and prostate cancer awareness His documentary Sustain, chronicling his cancer journey The importance of early detection for saving lives Montell also reminds listeners that a cancer diagnosis does not have to define the rest of your story. With faith, medical care, family support, and early intervention, there is hope—and there is life after cancer. Immortalize your voice by being an ALL TALK ONCOLOGY GUEST! Just fill-out this FORM. Invite Kenny Perkins to Speak or Participate on your event. Just fill-out this FORM.   SOCIAL MEDIA LINKS: All Talk Oncology: Instagram & Facebook JOIN OUR FREE COMMUNITY: Facebook Community WEBSITE: www.alltalkoncology.com  

50:02- John Solomon, award-winning investigative journalist, founder of "Just The News," and the host of “Just the News, No Noise” on the Real America’s Voice network Topic: Trump Accounts; Graham Planter; Accused Charlie Kirk killer in court; Other news of the day 59:05- Hans von Spakovsky, Senior Legal Fellow in the new Edwin Meese III Institute for the Rule of Law at Advancing American Freedo Topic: Alleged Charlie Kirk assassin Tyler Robinson's court appearance 1:12:21- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'” Topic: Current state of the U.S.-Israel relationship; Aftermath of negotiations in Doha 1:29:21- David Fischer, CEO of Landmark Capital Topic: Aggressive rise of stock indexes 1:40:47- Sheriff Shaun Golden, Monmouth County Sheriff Topic: BJ's roof collapse 1:48:53- Robert Greenway, Senior VP of American Global Strategies, Former Deputy Assistant to the President and Senior Director for the Middle East and North Africa in the Trump administration, and principal architect of the Abraham Accords Topic: Iranian performer calls for President Trump's assassination at Khamenei's funeral 2:01:23- Assemblywoman Dawn Fantasia, Republican representing New Jersey's 24th legislative district Topic: Why Mikie Sherrill hasn't called a State of Emergency in NJ 2:12:47- Dr. Gil Lederman, Expert in Prostate Cancer and the host of "Radiosurgery New York with Dr. Gil Lederman" on AM 970 The Answer Topic: His letter to the editor of the New York TimesSee omnystudio.com/listener for privacy information.

Dr. Ashwin Singh Parihar sits down with Dr. Louise Emmett to discuss how post-therapy Lutetium-177 PSMA SPECT/CT may help predict overall survival in patients with metastatic castration resistant prostate cancer and shape future treatment decisions. Drawing from the ENZA-p trial run by ANZUP cancer trials group, they explore quantitative imaging, treatment response assessment, adaptive dosing strategies, and the growing role of theranostics in precision oncology.   177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Ayati et al. Radiology 2026; 319(1):e252672.

With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for advanced prostate cancer? In this episode of BackTable Urology, Dr. Alan Tan is joined by Dr. Rana McKay and Dr. Emmanuel Antonarakis to discuss how evolving evidence, patient selection, timing, toxicity, and genetic testing are shaping the use of PARP inhibitor combinations in clinical practice. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction02:51 - PARPi Basics14:12 - Major Study Differences19:00 - Timing and Selection of PARPi Combinations26:39 - Case: Somatic BRCA2 loss and mHSPC35:51 - Case Continued: BRCA2 Reversion39:57 - BRCAAway Study42:59 - Takeaways from the 2026 APCCC --- More about this episode The conversation reviews lessons learned from major clinical trials, including PROpel, MAGNITUDE, TALAPRO-2, and AMPLITUDE, and addresses how these studies inform real-world treatment choices. The doctors dig into case examples, such as BRCA2 loss and reversion, and highlight practical strategies for using germline and somatic testing to personalize care. Key insights from the 2026 Advanced Prostate Cancer Consensus Conference are also shared, emphasizing the importance of precision medicine in this rapidly evolving field. --- Resources Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel) https://clinicaltrials.gov/study/NCT03732820 A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE) https://clinicaltrials.gov/study/NCT03748641?tab=study Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2) https://clinicaltrials.gov/study/NCT03395197 A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE) https://clinicaltrials.gov/study/NCT04497844 BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm) https://pubmed.ncbi.nlm.nih.gov/39115414/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Is “watchful waiting” for prostate cancer really the safest path—or could it be creating more harm than help?Today on Intellectual Medicine, Dr. Stephen Petteruti challenges the conventional use of watchful waiting and active surveillance in prostate cancer management. He argues that prostate biopsies and many standard treatment strategies often do little to improve long-term survival while subjecting patients to significant physical, emotional, and psychological burdens.Dr. Petteruti explains why he believes prostate biopsies have become outdated, questions the benefits of repeated surveillance procedures, and explores the stress and uncertainty that can accompany living with the ongoing fear of disease progression.The conversation also examines the potential side effects of prostate surgery and radiation therapy, including their impact on sexual function, urinary control, and overall quality of life.Rather than relying exclusively on PSA testing, biopsies, and imaging to drive treatment decisions, Dr. Petteruti advocates for a more proactive approach, one focused on optimizing overall health, supporting immune function, and preserving vitality while navigating a prostate cancer diagnosis.Timestamps:(00:00) Why watchful waiting feels like “water torture”(00:32) Why Dr. Petteruti believes the era of prostate biopsy should end(01:24) The limitations of surgery and radiation in prostate cancer care(02:50) Why biopsies cannot predict future disease behavior(04:45) Active surveillance vs. true treatment(06:00) The problem with labeling prostate cancer as “low risk”(07:20) PSA testing, MRI scans, and monitoring over time(09:00) Who should decide how prostate cancer is managed?(10:21) Why PSA trends matter more than a single result(11:55) Concerns about the side effects of surgery and radiation(14:10) The psychological burden of watchful waiting(15:18) A different approach: functional active treatment(16:12) The Prostate Vitality community and patient support(17:34) Challenging conventional thinking about prostate cancer managementEnjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a board-certified physician specializing in longevity-focused, integrative medicine. He works with men navigating prostate cancer, testosterone, and hormone health, aging, and performance using proactive, evidence-informed strategies grounded in real clinical practice. His approach prioritizes preserving function, strength, and quality of life while helping patients make clear, informed decisions beyond reactive, fear-driven care.Book: Fight Cancer Like a Man: https://tinyurl.com/FightLikeAManBookDr. Steve's email newsletter: https://drstephenpetteruti.substack.com/subscribePodcast show notes : https://www.intellectualmedicine.com/podcast-notesMember exclusive content: https://tinyurl.com/DrPetterutiMemberLearn more: https://www.drstephenpetteruti.com/ Learn more: https://www.intellectualmedicine.com/ Connect with Dr. Petteruti on:⁠Instagram: ⁠https://www.instagram.com/dr.stephenpetteruti/⁠ Facebook: ⁠https://www.facebook.com/dr.stephenpetteruti⁠ Disclaimer:The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.

What if failure isn't the opposite of winning — but the gift that makes it possible? In Part 2 of this two-part conversation, Your Health CEO Matt Staub opens up about the present he gave himself at 40: permission to fail. Then he shows what that looks like when life tests it — walking Jamie through a 2025 that brought prostate cancer, his daughter's surgery, the loss of his father, and professional hardship, and the quiet strength it takes to look back and say, "That was a good try. I'm still here. I'm hard to beat." In this episode, you'll hear: How Matt reframes a loss into a "fall forward" — and the simple habit he uses to do it The agonizing leadership question of when to let someone you care about fail Why accountability, done right, is one of the best gifts you can give a friend The danger of only celebrating big wins — and how complacency quietly creeps in Why the only voice that truly matters is the one inside your own head If you missed Part 1, start there for the full arc. Then settle in here for the deeper, more personal half — and walk away with a new relationship to the losses in your own life.

Summary:Brad Corley was diagnosed with stage 4 prostate cancer (Gleason 9) on December 10, 2021 — one day after retiring from a 38-year career. After bone scans and consultation with a New Orleans oncologist, the cancer was deemed metastatic and incurable but treatable; doctors gave him a 3-7 year outlook. Brad and his wife Becky had already begun shifting toward healthier living before the diagnosis, and immediately doubled down — adopting a raw, plant-based diet and daily carrot juicing (inspired by Chris Beat Cancer/Square One) starting just two days after the diagnosis. Brad underwent hormone therapy and surgery through an MD Anderson clinical trial. Over two and a half years, he dropped from about 240 to about 170 pounds, regained energy, and his oncologist reportedly told him he shows no evidence of disease. The couple credits their faith, gratitude practice, and community support — they started a Healing Strong group in Mobile, Alabama, with around 12-15 regular members, many of whom don't have cancer but joined proactively. The episode closes with their message to newly diagnosed listeners: lean on faith, build a supportive community, and pursue lifestyle changes alongside medical treatment.HealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please take advantage of our FREE resources below to help you along your health and healing journey:Support Group DirectoryHolistic Curriculum - Participant GuideSupport Our Mission - DonateAdditional Health ResourcesListen to Previous EpisodesWebsite: healingstrong.org

Featuring an interview with Dr Rana R McKay, including the following topics: Prostate Cancer Working Group (PCWG4) revised terminology (0:00) Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17) Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06) Takeaways from the Phase III EMBARK study (19:36) Use of CAR (chimeric antigen receptor) T-cell therapy and T-cell engagers (27:20) Potential role of circulating tumor DNA minimal residual disease testing; use of olaparib/radium-223 (29:24) CME information and select publications

Send us Fan MailFor decades, cancer treatment has rested on three pillars: surgery, chemotherapy, and external beam radiation. A fourth is now taking shape, and it is drawing billions in investment from some of the largest pharmaceutical companies in the world.John Babich, Founder, President, and Chief Scientific Officer of Ratio Therapeutics, joins host David E. Williams to explain how targeted radiotherapeutics pair a tumor-seeking molecule with a radioactive payload, delivering radiation to cancer cells while sparing healthy tissue. He also unpacks what Pluvicto's success in prostate cancer signals for the future of radioligand therapy.

Featuring a slide presentation and related discussion from Dr Rana R McKay, including the following topics: Overview of the current landscape of prostate cancer (0:00) Mechanism of action of androgen deprivation therapy (ADT) (3:51) Findings from the Phase III HERO study evaluating relugolix versus leuprolide for advanced prostate cancer (7:18) Real-world evidence regarding the use of relugolix (12:27) Adverse event profile associated with ADT (18:34) Case: A man in his early 70s with metastatic hormone-sensitive prostate cancer who receives ADT at various timepoints of treatment and is currently on relugolix (21:46) Case: A man in his early 60s with high-risk locally advanced prostate cancer who receives various androgen receptor pathway inhibitors in addition to relugolix (28:06) CME information and select publications

This week on The Armor Men's Health Show, Donna Lee sits down with Gregory Jacob Jr., a patient at Urology Specialists of Austin, to share his powerful and inspiring journey through prostate cancer. Gregory is also a public speaker and men's health advocate, especially relating to prostate cancer and recovery. Gregory opens up about his diagnosis as a Black man, discovering after his diagnosis that prostate cancer ran in his family, and the lifestyle changes he made—including adopting an alkaline diet to help reduce inflammation. He also candidly discusses overcoming erectile dysfunction, rebuilding his confidence, and why men should never let fear keep them from visiting the doctor.Gregory's mission is clear: to educate, encourage, and empower men to take charge of their health while inspiring them to overcome life's toughest challenges through faith, resilience, and action.Want to dive deeper into Gregory's message? Visit www.triedandapproved.com to learn more about his mission and to find all of his books, including:• TRIED & APPROVED: Faith. Fight. Heal. — A transformational workbook combining Gregory's personal testimony with practical guidance to help fathers, husbands, and sons overcome trauma, prostate cancer, and life's greatest obstacles.• The Alkaline Cookbook for Men: Fueling the Temple with Strength & Simplicity — A practical guide to nourishing your body through an alkaline-focused lifestyle.• TRIED & APPROVED: RESTORED: A 90-Day Protocol for Sexual Healing, Confidence, and God-Given Restoration — A faith-based roadmap for restoring sexual health, confidence, and overall well-being.Whether you're facing a health challenge yourself or want to support someone who is, this heartfelt conversation is filled with hope, practical advice, and the reminder that taking care of your health is one of the greatest gifts you can give yourself and your loved ones.Please share this important episode with your family, friends, and the men in your life. You never know whose life could be changed—or even saved—by hearing Gregory's remarkable story.

Is pelvic lymph node dissection still necessary in the era of PSMA PET imaging? In this episode of BackTable Urology, Dr. Ruchi Talwar interviews Dr. Kirsten Greene about how advanced imaging is influencing decisions for radical prostatectomy. They examine the strengths and limits of PSMA PET, the risks and benefits of PLND, and why careful, evidence-based decision-making remains essential. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction03:12 - Risk Calculators and Consent04:39 - Nomograms vs. Complications09:57 - Endpoints That Matter11:38 - PSMA PET Strengths and Limits13:51 - Negative PET Decision-Making15:08 - Positive PET and Multimodal Care18:02 - Fluorescence Guided Surgery19:10 - Counseling on Complications22:27 - Preventing Lymphocele24:56 - How Lahey Wrap Works26:45 - Future Mapping and Therapy28:47 - Research Gaps and Dogma31:07 - Key Pearls and Wrap Up --- More about this episode Dr. Greene explains her approach using MSK and Briganti nomograms alongside PSMA PET, noting that PET scans may miss small nodal disease and quality varies between centers. She emphasizes PLND as a staging tool rather than a curative procedure, outlining potential complications like lymphocele, lymphedema, vascular and ureteral injury, and neuropraxia. The episode highlights her shared decision-making process, surgical techniques for limiting risk, and the importance of multimodal planning, especially for PET-positive nodal disease. Dr. Greene also shares practical tips for lymphocele prevention, including the use of metal clips and the Lahey wrap. --- Resources Different lymph node dissection ranges during radical prostatectomy for patients with prostate cancer: a systematic review and network meta-analysishttps://pubmed.ncbi.nlm.nih.gov/36872312/ Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/33865797/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Serotonin is famous for what it does in the brain, but most of your serotonin isn't in your head at all! And don't miss the following topics that Terry will also discuss on this show: Serotonin, When the Diagnosis is Prostate Cancer, Nutrient of the Day: Melatonin, Lyme Disease.

Alan Morton experienced symptoms associated with prostate cancer, but it was some time before he sought medical attention.  Dating back to his teens, he had had a subpar urine flow, but in his sixties, he began to see blood in his urine.  He thought it might be a urinary tract infection, but when nothing had changed six months later, he contacted his doctor.  After various scans, a digital rectal exam and a biopsy, Alan was told he had Stage 3B prostate cancer.  It was later determined the cancer had metastasized to his pelvic and was re-diagnosed as Stage 4 Incurable.  He was placed on a hormone regimen including the injection of a drug called decapeptyl.  Alan said the side effects were awful, including fatigue, loss of muscle mass, weight gain and a severe loss of testosterone.  He suspects he will be on the hormone regimen for the rest of his life, but Alan Morton calls himself a prostate cancer endurant.  He still engages in hiking, and despite the handicaps, seeks to live life to the fullest.   It was in 2023 when Alan began to pass blood in his urine.  He didn't think this development was worth sharing with his wife or his doctor.  However, his wife saw what she thought was dark urine when Alan went to the bathroom and forgot to flush.  He told her he was passing blood and she immediately made a doctor's appointment for him.   Alan submitted to a digital rectal exam and provided a urine sample.  Although he thought the sample was "crystal clear," the doctor said the sample included "microscopic blood."  He was called in for another appointment, provided another blood sample.  From that and a biopsy, he received a diagnosis of Stage 3B prostate cancer.    Because of neck trauma stemming from a long ago auto accident, Alan could have his prostate removed.  His care team concluded the only available treatment option would be a hormone regimen, starting with androgen deprivation therapy, or ADT.  He said the effect it had on his body was awful.  They included fatigue, severe loss of testosterone, hair loss, plus weight gain in various places, among them, his breasts.  He was subsequently prescribed the injection of a drug, decapeptyl, and a pill called bucalutamide, designed to stop the growth of the tumor.  The ADT regimen stopped in October 2024, but the following month he began to pass blood again.  To make matters worse, his PSA, once at 0.037, rose sharply to 6.39 in April 2026.  Alan underwent a bone scan that indicated his cancer had spread to his pelvis.  He is back on ADT and expects he will be for the rest of his life.   Alan says his urinary function is outstanding but would rate his sexual function at something like 20 to 30 percent of what it was pre-diagnosis.   Alan Morton does not call himself a survivor of cancer, but rather an endurant.  He knows given his diagnosis and his hormone regimen, he is at reduced capacity, but aspires to live a full, rich life.   Additional Resources:   Support Group:   Fans for the Cure: https://www.fansforthecure.org      

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Brian Custer.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Brian Custer.

Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics: Introduction (0:00) Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41) Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16) CME information and select publications

Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast.   In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent FDA approvals in the GU space: PROTEUS:  trial comparing ADT monotherapy to apalutamide plus ADT in high-risk localized prostate cancer. We explored its findings, implications, and the ongoing debate surrounding its control arm. TALAPRO-3 Study: impact of PARP inhibitors combined with enzalutamide in metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) mutations. We discussed the nuances of HRR mutations and their clinical significance. CAPITELLO-281: insights into the recent approval of this AKT inhibitor for metastatic castration-sensitive prostate cancer with PTEN loss, based on the CAPItello-281 study. EV-302 update: combination of EV-pembrolizumab still maintains the doubling of survival benefit with longterm follow up. POTOMAC: durvalumab + BCG induction therapy for high-risk non-muscle invasive bladder cancer (NMIBC) could be a choice for a selected patient population. LITESPARK-022: The new approval of belzutifan with pembrolizumab in the adjuvant setting, discussing its efficacy and the importance of patient selection.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o ' Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Throughout the episode, we emphasized the importance of balancing treatment benefits with potential adverse events, as well as the need for shared decision-making in clinical practice. #GUOncology, #ASCO2026, #ProstateCancer, #BladderCancer, #RenalCellCarcinoma, #OncologyBrothers

In this EAU Podcast episode, Ass. Prof. Giancarlo Marra (IT), Prof. Derya Tilki (DE) and Prof. Philip Cornford (IE) discuss the latest updates in the 2026 EAU Guidelines on Prostate Cancer.They explore changes in risk stratification, the evolving role of enzalutamide plus ADT in high-risk disease, and emerging diagnostic technologies such as micro-ultrasound and NeuroSAFE. The conversation also highlights advances in personalised treatment approaches for metastatic hormone-sensitive prostate cancer, including BRCA and PTEN-targeted strategies.In addition, the speakers emphasise the growing importance of supportive care, bone protection, and managing long-term treatment-related side effects to improve patient outcomes.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In a hot seat coaching session on the #amwriting podcast, Jennie Nash coaches Brenna Humphries on a nonfiction proposal for Where It Hurts: A Couple's Guide to Kicking Prostate Cancer, noting a disconnect between the proposal's tone/claims and the sample chapters. They discuss how “salesy” positioning and language that can read as antagonistic toward the medical system may create legal and traditional publishing risks, especially when offering what could be construed as medical advice. Nash suggests shifting authority to lived experience and reframing the book as a framework for how couples navigate diagnosis and decision-making—using structures like key decisions, conversations, or “dates”—while keeping strong scene-based storytelling. Brenna agrees to substantially revise, aiming for a helpful stance that supports patients and partners with questions to ask, teamwork, and process rather than prescriptive medical directives.#AmWriting is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.Join the Blueprint Summer ChallengeStarting a book? Stuck in a draft? Planning a revision?The Blueprint Summer Challenge is designed to help you make meaningful progress on your manuscript this summer.Over six weeks, beginning July 10, you'll use the Blueprint—a proven framework for developing stronger books with greater clarity, purpose, and reader impact—to move your project forward, wherever you are in the process.Whether you're writing nonfiction, memoir, fiction, or another genre entirely, the goal is simple: spend six focused weeks making your book stronger.Start with the Blueprint CourseWe're offering an all-new Blueprint course in Teachable, which includes:The full text of The BlueprintFourteen video lessons covering every step of the frameworkReal coaching examples that show writers applying the Blueprint to their own projectsPractical guidance you can use immediatelyThe course is designed to help you develop a stronger foundation for your book—whether you're beginning from a blank page, working through a draft, or planning a revision.Course enrollment: $19

A new high-resolution MRI is offering a safer way to detect prostate cancer by helping doctors avoid risky biopsies that can lead to complications.

This Men's Health Month, Navigating Cancer TOGETHER sits down with Clarence Jones, prostate cancer survivor and one of Minnesota's most trusted names in community health.Clarence Jones, MA, CHW, CPH, CPE, is the Executive Director and Community Health Strategist of the Hue-MAN Partnership, a founding member of the organization he helped build into one of Minnesota's most trusted voices in public health. He serves as an Adjunct Instructor of Medicine at Mayo Clinic, is a founding member of the Minnesota Fathers and Families Network, has served as the Mayor's Representative and co-chair of the Public Health Advisory Committee for the City of Minneapolis, and holds affiliations with the CTSI Executive Leadership team and the University of Minnesota's CEARCH initiative. He is also a fatherhood doula, the host of the Community Health Dialogue radio show on KMOJ 89.9 FM, and co-host of the Health Chatter podcast.In this warm, honest, and personal conversation, Clarence opens up about his own journey through prostate cancer, from watching his PSA numbers climb year after year and practicing watchful waiting, to eventually choosing surgery. He shares why the digital exam scares men, and why early detection is the greatest gift you can give your family.But Clarence's story doesn't stop at survival. He shares how his experience deepened his mission to make sure the men and families in his community have access to credible, culturally relevant, evidence-based health information. That's the heartbeat of everything Hue-MAN does.You'll also hear him talk about what he wants every man facing a cancer diagnosis to know right now.✨ Episode Highlights:00:04:38 The Moment He Knew: Clarence's Prostate Cancer Journey00:09:22 How to Invite Men into Health Conversations Without Lecturing Them00:14:44 What Young Men Need to Know About PSA Screening and Biopsies00:27:45 Fatherhood Doula: What That Means and Why Fathers Matter00:36:55 What 'Navigating Cancer TOGETHER' Really MeansTranscript: https://bit.ly/podscript184Connect & Engage with ClarenceWebsite: www.huemanpartnershipalliance.orgHealth Chatter Podcast: www.healthchatterpodcast.comKMOJ Community Health Dialogue: 89.9 KMOJ FM

British TV celeb Jeremy Clarkson announced a cancer diagnosis on the latest episode of Clarkson's Farm. The 66-year-old pre-warned Instagram followers it would be a difficult watch, without revealing why. He let out the news in a sombre chat with programme stalwarts Kaleb Cooper and Charlie Ireland. UK Correspondent Enda Brady told Mike Hosking the one good thing that's come of it is the number of men now talking about prostate cancer and the test. He says Clarkson's shone a light on farming, and him making a full recovery from it and speaking about it will do a lot of good. LISTEN ABOVE See omnystudio.com/listener for privacy information.

This podcast features two of the investigators from the international, randomized, Phase III EMBARK trial (NCT02319837) in conversation. EMBARK evaluated the efficacy and safety of enzalutamide plus androgen deprivation therapy and enzalutamide monotherapy, as compared with androgen deprivation therapy alone, in patients with nonmetastatic castration-sensitive prostate cancer and biochemical recurrence at high risk for metastasis. In this podcast, the second in the EMBARK series, the speakers discuss the key efficacy and safety findings from the trial, consider some of the patient-reported outcomes and their implications for quality of life, and review some of the implications for clinical practice.

Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12) Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54) Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49) Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath (1:13:12) Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad (1:37:26) CME information and select publications

What Causes Cancer? The Truth Most Doctors Don't Talk AboutIn this episode of Intellectual Medicine, Dr. Stephen Petteruti explores the relationship between cancer, metabolism, sugar, insulin, body fat, and prostate cancer progression. He discusses the Warburg theory, which suggests that cancer may begin with dysfunctional mitochondrial metabolism, and compares it with the later focus on genetic causes of cancer. While he argues that the idea of “starving cancer” by eliminating sugar is too simplistic, he also emphasizes that metabolic health plays a real role in cancer risk and progression.The episode focuses heavily on prostate cancer, which Dr. Petteruti describes as unique compared with other cancers. He argues that conventional approaches often overlook the environment in which cancer develops, including excess body fat, high insulin, elevated blood sugar, inflammation, and poor metabolic health. He also discusses tests such as fasting insulin, hemoglobin A1c, and continuous glucose monitoring, as well as the importance of nutritional and behavioral change. The episode closes with a warning against extreme diets, oversimplified supplement advice, and one-size-fits-all cancer theories.Timestamps:(00:00) What Causes Cancer?(01:02 )The Warburg Theory(02:14) Genetics vs. Metabolism(04:22) Why “Starving Cancer” Is Too Simplistic(05:42) Body Fat, Insulin, and Prostate Cancer(08:30) Tests That May Help Assess Metabolic Health(10:47) Food, Weight Loss, and Cancer Risk(13:42) The Anti-Cancer Lifestyle(15:04) Toxins, Viruses, and Parasites(16:15) NAD, Mitochondria, and Supplement Caution(17:33) Growth Hormone, IGF-1, and Cancer Risk(19:12) Why Extreme Dieting Is Not the AnswerEnjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a board-certified physician specializing in longevity-focused, integrative medicine. He works with men navigating prostate cancer, testosterone, and hormone health, aging, and performance using proactive, evidence-informed strategies grounded in real clinical practice. His approach prioritizes preserving function, strength, and quality of life while helping patients make clear, informed decisions beyond reactive, fear-driven care.Book: Fight Cancer Like a Man: https://tinyurl.com/FightLikeAManBookDr. Steve's email newsletter: https://drstephenpetteruti.substack.com/subscribePodcast show notes : https://www.intellectualmedicine.com/podcast-notesMember exclusive content: https://tinyurl.com/DrPetterutiMemberLearn more: https://www.drstephenpetteruti.com/ Learn more: https://www.intellectualmedicine.com/ Connect with Dr. Petteruti on:⁠Instagram: ⁠https://www.instagram.com/dr.stephenpetteruti/⁠ Facebook: ⁠https://www.facebook.com/dr.stephenpetteruti⁠ Disclaimer:The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.

Prostate cancer is the most commonly diagnosed cancer among men and remains a leading cause of cancer-related death worldwide. While age, family history, and genetics are well-established risk factors, researchers have increasingly focused on the role of metabolic health in prostate cancer progression. Obesity, insulin resistance, type 2 diabetes, and chronic inflammation have all been associated with more aggressive disease, but the molecular mechanisms connecting these conditions to prostate cancer remain incompletely understood. A research paper titled “Epigenetic dysregulation and biological function of PDX1 in prostate cancer” was published in Volume 17 of Oncotarget. In this study, the researchers investigated whether a gene best known for regulating pancreatic function may also play an important role in prostate tumor biology. The study was led by first author Tayo A. Adeyika and corresponding author Bernard Kwabi-Addo from Howard University, Washington, DC. Full blog - https://www.oncotarget.org/2026/06/16/pdx1-may-link-metabolic-dysfunction-to-prostate-cancer-progression/ DOI - https://doi.org/10.18632/oncotarget.28854 Correspondence to - Bernard Kwabi-Addo - bkwabi-addo@howard.edu Abstract video - https://www.youtube.com/watch?v=itYVsyXJJoE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28854 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PDX1, DNA methylation prostate cancer, shRNA knockdown, over-expression, glucose To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this episode of The Penis Project Podcast, Melissa sits down with Don and Clare, a couple who have lived through the messy, emotional and often under discussed reality of prostate cancer recovery.  Don was diagnosed just before his 65th birthday after his PSA rose from around 4 to over 9. A biopsy showed aggressive Gleason 9 prostate cancer, and within six weeks his prostate was removed. His PSA is now undetectable, which is the result everyone hopes for. But, as Don and Clare explain, being “cancer-free” did not mean life went back to normal.   After surgery, Don experienced severe ongoing urinary incontinence. Despite doing all the pelvic floor exercises and following instructions, he was still incontinent 18 months later. Eventually, after further review, he was referred for an artificial urinary sphincter, which has made a huge difference to his quality of life.   This episode is about more than leakage, pads, clips and surgery. It is about what happens when a man feels lost in the medical system. It is about the emotional toll of prostate cancer on both partners. It is about the importance of honesty, asking questions, changing teams if needed, and remembering that there is a person attached to the prostate.  In This Episode, We Cover:  The emotional impact of severe urinary leakage   Why pelvic floor exercises do not fix every case of incontinence   What can be done when continence doesn't recover  Clare's perspective as a partner watching Don struggle   How hormone therapy affected Don's mood, personality and relationship   The importance of being told the full picture, not just the “curative” plan   Why some men need an artificial urinary sphincter   The importance of second opinions and finding a team that sees the whole person   Why prostate cancer recovery is a couple's issue, not just a man's issue    Key Takeaway: An undetectable PSA is wonderful, but it is not the whole story; quality of life matters.    Key message from Don and Clare:   People need honest information.  Don and Clare do not regret the cancer treatment. Don says the surgery likely saved his life. But they both wish they had been told earlier that his continence recovery was unlikely to happen without further intervention. Clare explains that people may not want bad news, but they do want the truth.  That truth gives people options. It helps them plan. It helps them understand that they are not failing. And it can prevent months, or even years, of unnecessary suffering.    Resources & Links:  Book a telehealth consult with our sexual health nurse practitioners at Restorative Health Clinic  For more information check out our websites www.rshealth.com.au , www.makehardeasy.com.au and www.melissahadleybarrett.com.au   Listen & Subscribe  If you found this episode helpful, don't forget to subscribe, rate, and review the podcast! Your feedback helps us continue bringing important conversations to light. Search for The Penis Project Podcast on Spotify, Apple Podcasts, or your favourite podcast app.  Connect With Us   We love hearing from real people navigating penile health. If you'd like to share your journey or ask a question, get in touch.     Email: admin@melissahadleybarrett.com    Websites:  https://rshealth.com.au/  All genders  https://makehardeasy.com.au   https://melissahadleybarrett.com   http://prost.com.au/   Instagram:  https://www.instagram.com/melissahadleybarrett/  https://www.instagram.com/restorativehealth.clinic/    YouTube: https://www.youtube.com/@melissahadleybarrett   TikTok: @melissahadleybarrett    Facebook:  https://m.facebook.com/p/Melissa-Hadley-Barrett-100085237672685/  https://www.facebook.com/profile.php?id=100085146627814    Linkedin:  https://www.linkedin.com/in/melissa-hadley-barrett/   TEDX  https://www.youtube.com/watch?v=IjHj1YTmLoA   

Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.

Kevin Boston-Hill speaks with Naismith Basketball Hall of Famer Nancy Lieberman, and Chief Philanthropy Officer of the Prostate Cancer Foundation, Lori Tessel, about how important it is to have prostate cancer screening. Those who get screened and detect the cancer early have a 99% survival rate.

AUA Guidelines: Clinically Localized Prostate Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: James Eastham, MD, FACS To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/clinically-localized-prostate-cancer

Learn about the Healing Power of Prolonged Fasting: HEREWhat if the prostate treatment your doctor recommended wasn't your only choice?Joel Pruttis came to Dr. Katie Deming with a rising PSA, a lesion seen on his prostate MRI, and a urologist telling him he probably had cancer. But something about it didn't sit right, so he paused, did his research, and made a choice many people in his position may never hear about.Dr. Katie and Joel talk through what it's like to face a scary diagnosis, feel pushed toward a system that doesn't quite feel right, and find the courage to try something different. Joel's story centers on prostate health, but the questions he wrestled with will feel familiar to anyone who has ever wondered if there's another way.Chapters:00:06:17 - Why the MRI Room Changed Everything00:07:09 - Two PSA Numbers, One Big Question00:09:17 - The Reason He Trusted Dr. Katie00:10:09 - The Part of Fasting That Scared Him Most00:11:45 - Why He Took the Leap Anyway00:13:09 - What 14 Days Without Food Actually Felt Like00:14:52 - The Subtle Shift That Told Him It Was Working00:16:13 - The Treatment Path He Almost Walked Into00:23:37 - The Health Changes He Didn't Expect00:29:30 - The Decision That Could Have Changed His Life00:34:40 - The Cost Comparison No One Talks About00:38:47 - The Healing Path Hidden in Plain SightIt's not only about Joel's lab results after a 14-day water fast, but everything else that shifted along the way, things he wasn't even looking for when he started.If you've ever felt stuck between fear and uncertainty, or wondered whether the standard path is really your only option, stay until the end. Joel shares exactly what he would say to anyone standing at that crossroads right now.Press play and learn what happened when one man decided to trust his body first.Join Dr. Katie's 3-Day Guided Fast, for expert support, daily live calls, and a community to fast alongside: Sign-Up Follow Dr. Katie Deming on InstagramWatch on YoutubeDISCLAIMER: The Born to Heal Podcast  is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.A thought-provoking podcast explores cancer through the lens of holistic medicine and functional medicine, discussing causes of cancer, metabolic health, and unconventional approaches like water fasting, fasting and autophagy, and detox, while weighing fasting benefits against chemo side effects and radiation side effects, sharing stories of a cancer survivor navigating chemotherapy, natural medicine, holistic healing, and even spiritual healing on the path toward cancer remission and holistic health. 

Can you really treat prostate cancer effectively without knowing the genetics? In this episode of BackTable Urology, Dr. Evan Yu and Dr. Tanya Dorff join host Dr. Alan Tan to discuss why genetic testing is essential in personalized prostate cancer care. They discuss when and how to perform germline and somatic testing, address common barriers, and share best practices for counseling patients. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction02:18 - Who Gets Somatic Testing?06:43 - Patient Barriers to Testing09:00 - Genetic Testing Workflow12:28 - Treating BRCA2 Alterations24:18 - Monitoring Progression: ctDNA vs. PSA vs. Imaging29:32 - Treating mCRPC with ATM Mutations34:39 - CDK12 Classification 37:43 - Closing Takeaways --- More about this episode The doctors explore how BRCA2 and other DNA repair alterations can directly shape treatment decisions, focusing on the roles of PARP inhibitors and platinum therapy in advanced cases. The discussion highlights why both germline and somatic testing are critical for identifying actionable mutations and discuss the nuances of interpreting test results, including current limitations and emerging biomarkers. They also examine challenges such as insurance coverage, patient misconceptions, and workflow integration, as well as the movement toward truly personalized, biology-driven approaches in prostate cancer care. --- Resources Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial:https://pmc.ncbi.nlm.nih.gov/articles/PMC12705445/ Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study:https://www.annalsofoncology.org/article/S0923-7534(25)04936-1/fulltext Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer:https://www.nejm.org/doi/full/10.1056/NEJMoa1903307 ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patientshttps://www.sciencedirect.com/science/article/pii/S0302283825048766 First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer:https://www.nejm.org/doi/abs/10.1056/NEJMoa2502929 PROMISE Registry:https://www.prostatecancerpromise.org/ Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00683-X/abstract --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Steven Seyedin discusses radiation therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41558]

Leave a message and let us know what you liked about the episode!Survivor's guilt is a common and not often talked about emotional experience after cancer. Dr. Leah Sherman sits down with returning guest Natasha Ewa, licensed clinical social worker and founder of I Thrive Therapy and Wellness, for an honest conversation about what survivor's guilt actually looks like, why body image after cancer is so personal, and what healing can feel like on the other side.The conversation widens to cover grief over pre-cancer identity, hypervigilance, reconstruction decisions, and Natasha's documentation of her own DIEP flap experience and complications.Whether you're navigating survivorship yourself or supporting someone who is, this one meets you where you are.Visit the I Thrive Therapy and Wellness websiteFollow Natasha on InstagramSupport the showBecome a member of The Cancer Pod Community! Gain access to live Q&As, exclusive content, and so much more! Join us today on Buy Me a Coffee or on Patreon!Check out our website! Looking for more information? We have blogs, merch, and all of our episodes listed by season and category. Shop our favorite reads! We've joined with Bookshop.org to offer some of our fave books!Buy our merch! Whether it's a cozy hoody or a handy water bottle, we have something for everybody.Have a comment or suggestion? Email us at info (at) thecancerpod (dot) com Follow us wherever you browse. We're always @TheCancerPod:InstagramBlueskyFacebookLinkedInYouTubeTHANK YOU!!

Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.

If Part 1 was about the field of sexual medicine, Part 2 is about the marriage at the center of it. Dr. Jenni Skyler and Daniel Lebowitz return to their conversation with Dr. Irwin and Sue Goldstein, and this time, the questions get more personal. How do you stay married for fifty years? What does great sex actually look like across the decades? And what happens when a woman who has spent her career in sexual medicine starts experiencing low desire herself? Sue Goldstein opens up about her own journey through peri-menopause and the slow erosion of her libido- what she calls "duty sex", and the medications that brought not just her sex drive back, but a playfulness in her marriage she hadn't realized had gone missing. She walks listeners through her menopause toolbox of five treatments, explains why she's "76 and feels like she's in her 50s", and dismantles the lingering fears from the Women's Health Initiative that have kept generations of women in what she calls hormone prison. Dr. Irwin shares his own daily protocols for sexual health, why he believes most older men are leaving capacity on the table, and the surprising data from their own clinic- that more than half the Vyleesi prescriptions they write are off-label for men. They explore why dopamine is dopamine, regardless of gender. The reality of persistent genital arousal disorder. And a remarkable story of a teenage horseback rider whose chronic arousal turned out to be a herniated disc. This episode is full of practical wisdom, clinical innovation, and one of the most real conversations about long-term love you'll hear all year. The Goldsteins' secret to fifty years of marriage? Best friends, good sex, and the willingness to keep trying new things — including a chocolate sauce on the day before you change the sheets. Irwin Goldstein, MD, IF (he/him/his). Director, San Diego Sexual Medicine 5555 Reservoir Drive, Suite 300, San Diego, CA 92120, Director, Sexual Medicine, UC San Diego Health East Campus, San Diego, CA. Clinical Professor of Urology, University of California at San Diego. Voluntary Clinical Professor of Obstetrics, Gynecology and Reproductive Services Past President, International Society for the Study of Women’s Sexual Health. Past President, Sexual Medicine Society of North America. Editor Emeritus, Sexual Medicine Reviews, The Journal of Sexual Medicine, International Journal of Impotence Research. Phone: 619 265-8865 - Mobile: 619 987-7432. Email: dr.irwingoldstein@gmail.com. http://www.sandiegosexualmedicine.com. Like us on Facebook: https://www.facebook.com/SDSexMed. X: http://twitter.com/SDSexualMedSee omnystudio.com/listener for privacy information.

This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, challenges, and future directions in radiopharmaceuticals.